Abbott Reports (MOMENTUM 3) Trial Results of HeartMate 3 Heart Pump for the Treatment of Advanced Heart Failure
Shots:
- The company reported the results from the (MOMENTUM 3) trial evaluating the long-term outcomes of the HeartMate 3 left ventricular assist device in patients with advanced heart failure
- The results showed that the heart pump helps to extend the survival to 5yrs. and beyond for HF patients, improvement in a survival rate of 58% with HeartMate 3 Heart Pump over 44% with HeartMate II, reduction in deaths due to stroke, clotting, and bleeding over HeartMate II
- The device also provides clear lifesaving options along with a significant survival benefit of Abbott's heart pump technology without a heart pump or transplant who have limited therapeutic options with a median survival to ≤1yr.
Ref: Abbott | Image: Abbott
Click here to read the full press release
Neha is a Senior Editor at PharmaShots. She is passionate and very enthusiastic about recent updates and developments in the life sciences and pharma industry. She covers Biopharma, MedTech, and Digital health segments along with different reports at PharmaShots. She can be contacted at connect@pharmashots.com.
